As part of our continual presence in Washington, DC, and around the United States, whenever appropriate IFFGD offers testimony to the U.S. Food and Drug Administration (FDA) and other regulatory agencies. Through either written or in-person statements, we share the perspective of functional gastrointestinal (GI) and motility disorder patients. We urge consideration of the patient perspective in regulatory decisions and encourage additional resources to help meet their needs.
The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2019-D-4247
The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2015-D-2479
The following written comments were submitted to the Office of Disability Policy of the Social Security Administration (SSA) by IFFGD President, Ceciel T. Rooker, in response to Docket
The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2019-N-0077
The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Social Security Administration (SSA) in response to Docket No. SSA-2018-0017
The following comments were submitted by IFFGD President, Ceciel T. Rooker, to the US Department of Health and Human Services (HHS) in regards to Docket
The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Department of Defense (DoD) in connection with a January 10,
The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Food and Drug Administration (FDA) in connection with a
The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Food and Drug Administration (FDA) in connection with a October
On September 12, 2017, Ceciel Rooker presented the following research information to the US Food and Drug Administration (FDA) concerning the burdens and needs of
On May 11, 2015, Tegan Gaetano took part in and presented the following comments on behalf of IFFGD members at the FDA Patient-Focused Drug Development
IFFGD Vice President, William Norton, submitted the following written comments to Noridian Administrative Services in response to the decision by Noridian to deny Medicare coverage
This information is in no way intended to replace the guidance of your doctor.
We advise seeing a physician whenever a health problem arises requiring an expert’s care.
© Copyright 2024 International Foundation for Gastrointestinal Disorders, Inc. (IFFGD).
All Rights Reserved.
Keep up-to-date on the latest news, stories, tips, research highlights, and more!
